{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:30:31Z","timestamp":1784752231316,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"LEO Pharma BV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriasis is most often treated using topical therapies such as the once\u2010daily fixed combination of calcipotriol and betamethasone dipropionate, which is available as a gel and an ointment. To date, there have been no direct comparisons of patient perspectives on the two formulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe and compare patients' perspectives on calcipotriol and betamethasone gel and ointment formulations, including real\u2010life effectiveness, adherence behaviour, treatment satisfaction and health\u2010related quality of life (QoL), during long\u2010term psoriasis vulgaris management, according to interim findings from the <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\u2010long study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\u2010long is a multicentre, prospective, observational, 52\u2010week cohort study in patients prescribed fixed\u2010combination calcipotriol (50\u00a0\u03bcg\/g) and betamethasone (0.5\u00a0mg\/g; as dipropionate) gel or ointment for long\u2010term psoriasis management. Difference in effectiveness at 4 and 12\u00a0weeks was assessed by comparing the proportion of patients with controlled (mild or very mild) disease, according to the Patient's Global Assessment. Additional patient questionnaires were used to assess adherence behaviour, treatment satisfaction (nine\u2010item Treatment Satisfaction Questionnaire for Medication) and health\u2010related QoL (Skindex\u201029).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 156 patients were included in the analysis. In single items of the adherence behaviour and treatment satisfaction questionnaires, patients preferred the gel over the ointment as convenient, easy to use and fast to apply. <jats:italic>Post hoc<\/jats:italic> analysis demonstrated significant differences between gel and ointment for convenience and application time. More patients had controlled disease at week 12 with gel (71.9%) vs. ointment (65.7%); however, the difference was not statistically significant (primary end point; <jats:italic>P\u00a0<\/jats:italic>=\u00a00.40).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This interim analysis supports fixed\u2010combination calcipotriol and betamethasone gel as more convenient, easier to use and faster to apply than the ointment formulation in real\u2010life conditions according to patients with psoriasis vulgaris. Furthermore, a numerical difference in patient\u2010reported real\u2010life effectiveness was seen in favour of the gel, although this was not statistically significant.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12387","type":"journal-article","created":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T13:01:42Z","timestamp":1392642102000},"page":"1723-1731","source":"Crossref","is-referenced-by-count":17,"title":["Real\u2010life effectiveness of once\u2010daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4\u2010 and 12\u2010week interim results from the <scp>PRO<\/scp>\u2010long study"],"prefix":"10.1111","volume":"28","author":[{"given":"J.","family":"Lambert","sequence":"first","affiliation":[{"name":"Department of Dermatology Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.W.","family":"Hol","sequence":"additional","affiliation":[{"name":"LEO Pharma BV Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vink","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Centrum Haaglanden Westeinde Hospital The Hague The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.319"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.12968\/bjcn.2012.17.11.524"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12174"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_6_10_1","first-page":"636","article-title":"Chronic plaque psoriasis","volume":"73","author":"Luba KM","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04059.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_6_15_1","unstructured":"Scottish Medicines Consortium.Calcipotriol and betamethasone dipropionate 50 micrograms\/g\u00a0+\u00a0500 microgram\/g gel (Xamiol\u00ae). No. (559\/09).2009. URLhttp:\/\/www.scottishmedicines.org.uk\/files\/Microsoft_Word_\u2010 _calcipotriol_and_betamethasone_dipropionate__Xamiol__FINAL_July_2009_for_ website.pdf (last accessed 12 June 2013)."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04518.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12029_suppl"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/11634710-000000000-00000"},{"key":"e_1_2_6_19_1","first-page":"32","article-title":"The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis","volume":"79","author":"Stein GL","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7211.652"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00186.x"},{"key":"e_1_2_6_22_1","unstructured":"US Food and Drug Administration.Guidance for industry. Patient\u2010reported outcome measures: use in medical product development to support labeling claims.2009. URLhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf (last accessed: 30 May 2013)."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06502.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470111018"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11207300-000000000-00000"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S24752"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.028"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:45:18Z","timestamp":1695570318000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,17]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/jdv.12387"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12387","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,17]]}}}